OptimizeRx (NASDAQ:OPRX) Price Target Cut to $18.00 by Analysts at Roth Mkm

OptimizeRx (NASDAQ:OPRX) had its price target lowered by investment analysts at Roth Mkm from $32.00 to $18.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Roth Mkm’s price objective would suggest a potential upside of 182.57% from the stock’s current price.

OPRX has been the topic of several other research reports. Weiss Ratings restated a “sell (d+)” rating on shares of OptimizeRx in a research note on Monday, December 22nd. Stephens cut their target price on OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Friday. Stifel Nicolaus reduced their price target on OptimizeRx from $21.00 to $17.00 and set a “buy” rating for the company in a report on Friday. Wall Street Zen upgraded shares of OptimizeRx from a “buy” rating to a “strong-buy” rating in a research note on Sunday, December 14th. Finally, Zacks Research lowered shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 15th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $17.17.

OptimizeRx Trading Down 15.4%

NASDAQ OPRX traded down $1.16 during trading on Friday, hitting $6.37. The company had a trading volume of 1,432,824 shares, compared to its average volume of 390,957. The company’s fifty day moving average is $10.63 and its 200-day moving average is $14.80. OptimizeRx has a one year low of $3.99 and a one year high of $22.25. The company has a current ratio of 3.05, a quick ratio of 3.05 and a debt-to-equity ratio of 0.20. The company has a market cap of $118.74 million, a price-to-earnings ratio of 19.67 and a beta of 1.20.

OptimizeRx (NASDAQ:OPRX) last announced its earnings results on Saturday, January 31st. The company reported $0.51 EPS for the quarter. OptimizeRx had a net margin of 0.03% and a return on equity of 6.37%. On average, sell-side analysts predict that OptimizeRx will post -0.33 earnings per share for the current year.

OptimizeRx declared that its Board of Directors has authorized a share buyback program on Thursday, March 5th that allows the company to repurchase $10.00 million in shares. This repurchase authorization allows the company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

Institutional Trading of OptimizeRx

A number of hedge funds have recently bought and sold shares of OPRX. Nisa Investment Advisors LLC lifted its position in OptimizeRx by 600.0% during the second quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock valued at $29,000 after purchasing an additional 1,818 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of OptimizeRx in the second quarter worth about $44,000. BNP Paribas Financial Markets raised its holdings in shares of OptimizeRx by 119.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after acquiring an additional 2,215 shares in the last quarter. State of Alaska Department of Revenue bought a new stake in shares of OptimizeRx in the 4th quarter worth about $62,000. Finally, USA Financial Formulas bought a new stake in OptimizeRx during the third quarter worth approximately $131,000. Hedge funds and other institutional investors own 76.47% of the company’s stock.

More OptimizeRx News

Here are the key news stories impacting OptimizeRx this week:

• Positive Sentiment: Q4 results topped estimates — OPRX reported $0.51 EPS and $32.24M in revenue, beating consensus and highlighting continued revenue growth. This is the fundamental positive underpinning the shares. GlobeNewswire: Press Release
• Positive Sentiment: Board authorized a $10.0M share repurchase (up to ~6.8% of shares), a signal management views the stock as undervalued and a potential support for the share price. RTT News: Buyback
• Neutral Sentiment: Company-hosted earnings call and multiple transcripts are available for investors to assess management commentary and execution plans; useful for judging sustainability of growth and margin outlook. Yahoo Finance: Earnings Highlights
• Neutral Sentiment: Trading experienced repeated LULD pauses (multiple intraday halts) — this indicates elevated volatility and may have contributed to larger intraday moves and volume. (Market notices reported multiple LULD pauses.)
• Negative Sentiment: FY‑2026 revenue guidance of $109M–$114M came in materially below the consensus (~$122M), creating the primary negative catalyst pushing the stock lower as investors reprice forward growth expectations. Seeking Alpha: Guidance
• Negative Sentiment: Stephens cut its price target from $17 to $10 and moved to an “equal weight” rating, sending a clear signal to investors and likely amplifying selling pressure from analysts/quant strategies. Benzinga: Analyst Note

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.